The Journal of Neuroscience smacked expressions of concern on two papers linked to the maker of a drug to treat Alzheimer’s, according to a report by ReactionWatch on Monday.

  • Cassava Sciences was under significant scrutiny. In August, the law firm Labaton Sucharow, which represents Cassava short-sellers, presented a “citizen’s petition” to the FDA.
  • The Petition had huge concerns about the quality and integrity of the laboratory-based research studies relating to the drug candidate and supporting the claims for its efficacy.
  • In November, the Wall Street Journal reported that the company has been under probe by the Securities and Exchange Commission for questions about whether it presented manipulated data for simufilam.
  • The two expressions of concern relate to articles in the Journal of Neuroscience published in 2009 and 2012. The medical papers have been cited 95 and 35 times.

The action of the journal attracted mixed reactions on social media, where some users praised the move while others argued the move was long overdue. SAVA up +19.36%.